In this article, we will list the 5 Best Mid-Cap Stocks That Could Double Your Money. Please visit 10 Best Mid-Cap Stocks That Could Double Your Money if you’d like to see an extended list and the methodology behind it.
5. Structure Therapeutics Inc. (NASDAQ:GPCR)
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money.
On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the stock.
Source:unsplash
H.C. Wainwright noted that Retatrutide’s clean low-dose profile alongside Pfizer’s once-monthly injectable establishes a new benchmark within the identical mid-body mass index market that oral treatments are targeting. Consequently, the firm cited increasing competitive pressure as the primary reason for the price target reduction.
On June 6, Structure Therapeutics Inc. (NASDAQ:GPCR) announced Phase 2b ACCESS trial results for aleniglipron in Nature Medicine. A lower 2.5 mg starting dose improved tolerability. Furthermore, weight loss persisted beyond 36 weeks, shaping the Phase 3 trials scheduled for the third quarter of 2026.
Patients actually kept shedding weight during the extension phase without hitting a plateau. According to Steering Committee Chair Dr. Julio Rosenstock, MD, this continuous weight loss makes the daily oral drug a highly unique option for patients.
Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs. The company is currently working on several drug candidates, which include GSBR-1290, ACCG-2671, ACCG-3535, LTSE-2578, and ANPA-0073. Additionally, it also develops programs like the GCG and GIPR programs.
4. Vaxcyte Inc. (NASDAQ:PCVX)
Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money.
On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus in healthy adults aged 18 to 40 years.
The company anticipates reporting topline data from the study in the second half of 2027. The primary objective of the randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is to assess the safety and tolerability of VAX-A1, while the secondary objective is to evaluate initial immunogenicity data.
Stage 1 will evaluate three dose levels compared to a placebo in approximately 12 adults. Following independent Data Safety Monitoring Board approval, Stage 2 will evaluate the same dose levels in approximately 68 adults.
Speaking about this development, Grant Pickering, CEO and Co-Founder of Vaxcyte, stated that initiation of the study represents an important milestone in addressing a significant global public health challenge with no approved vaccine. Furthermore, Jim Wassil, EVP and COO, noted that Group A Strep is responsible for a wide spectrum of diseases.
Vaxcyte Inc. (NASDAQ:PCVX) is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.
3. Vera Therapeutics Inc. (NASDAQ:VERA)
Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 10 best mid-cap stocks that could double your money.
On June 2, Vera Therapeutics, Inc. (NASDAQ:VERA) announced that it reached an agreement with the U.S. Food and Drug Administration regarding an accelerated timeline for its ORIGIN 3 eGFR analysis plan. This revised approach is intended to support the full regulatory approval of atacicept for adult patients suffering from IgA nephropathy (IgAN).
The third quarter of 2026 is when the eGFR findings are anticipated to be released, while in the fourth quarter of 2026, Vera plans to file a supplemental Biologics License Application (sBLA) for complete regulatory approval, contingent on the results of the data. Additionally, the modified regulatory approach was supported by past eGFR data from the company’s ORIGIN Phase 2b clinical trial.
Marshall Fordyce, M.D., the Founder and CEO of Vera Therapeutics, noted that this modification highlights the medication’s potential to be the first licensed treatment for adult IgAN patients that targets both BAFF and APRIL. He also mentioned the possibility of accelerating full market approval by advancing the data analysis timeline.
Vera Therapeutics Inc. (NASDAQ:VERA) is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases such as immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.
2. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best mid-cap stocks that could double your money. Based on consensus estimates, as of June 12, the stock offers more than 159% upside potential at the current level.
On June 11, Leerink analyst Joseph Schwartz maintained an Outperform rating on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) following a regulatory setback for a potential rival company. Camurus received a complete response letter regarding its application for Oclaiz, a targeted treatment for acromegaly.
Camurus made it clear that observations from a September 2024 cGMP inspection at a third-party manufacturing site are the direct cause of this rejection. Notably, this marks the second such rejection for this specific application.
According to the analyst, Crinetics Pharmaceuticals will benefit greatly from this development. He explained that during the crucial initial phases of Palsonify’s commercial deployment, the complete response letter effectively prevents a potential rival from entering the U.S. market.
As a result, it won’t have to deal with pressure from a new branded competitor entering the acromegaly market. Additionally, this provides Crinetics with more time to aggressively build physician familiarity, enhance payer onboarding processes, and convert early patient interest.
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.
1. Viking Therapeutics Inc. (NASDAQ:VKTX)
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money.
On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. (NASDAQ:VKTX) while setting a price target at $89. This leads to an upside potential of more than 211% at the prevailing level.
According to the firm, this stance is driven by the market opportunity for VK2735, the company’s lead clinical asset for obesity. VK2735 is projected to generate approximately $3 billion in risk-adjusted worldwide sales by the year 2040. Additionally, the firm noted the potential for further financial upside stemming from the company’s earlier-stage pipeline assets.
On May 27, Truist published a report on Viking Therapeutics Inc. (NASDAQ:VKTX) with a Buy rating and a price target of $83, indicating a 191% upside. The firm highlighted the company as a distinct competitor within a crowded and highly aggressive obesity treatment market.
The company effectively addresses two major hurdles found in existing and emerging treatments, which include long-term patient compliance and rapid time to efficacy, pointing to the achievement of 14.7% weight loss within 13 weeks without hitting a plateau.
Furthermore, Truist emphasized that by offering both the oral and subcutaneous delivery options, the company enables a continuous care model with adaptable dosing and flexible titration. This versatility allows for greater clinical personalization while helping to reduce gastrointestinal side effects.
Viking Therapeutics Inc. (NASDAQ:VKTX) specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.
While we acknowledge the potential of VKTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VKTX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
